2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5311 Impact of extranodal disease on CD20/CD3 bispecific antibody outcomes in relapsed/refractory follicular lymphoma: A GELTAMO study

Marc Bosch Schips, MD, Mariana Bastos-Oreiro, MD, PhD2, Ana Jiménez Ubieto, MD, PhD3, Ana Muntanola, MD PhD4, Jonay Méndez, MD5, Maria Jose Rodriguez Salazar6, Pablo Manresa Manresa7, Begona Mendibil8, Diego Clavo Martin9, Laura Magnano, MD, PhD10, Maria Sofia Vazquez Diaz Jr, PhD11, Carolina Martinez Gómez Sr12, Ruben Fernández Álvarez13, Hugo Daniel Luzardo Henríquez14, Eva Donato, PhD15, Ilda Murillo16, Elena Perez Ceballos17, Francisco Javier Diaz Galvez, MD18, Pilar Gomez Prieto, MD19, M Jimena Cannata20, Maria Teresa Busnego Barreto21, Mª Ángeles Goñi Herranz22, Lucia Villalon Blanco23, Pilar Martinez-Barranco24, Cristina Barrenetxea Lekue, PhD25, Ana Torres Tienza, PhD26, Angel Serna, MD27, Irati Ormezabal28, Blanca Sánchez-González29, María Civeira Marin30, Raquel Del Campo31, Sonia González De Villambrosia32, Antonio Gutierrez, MD33, Miguel Ángel Rodríguez Gil34, Nazaret Domínguez35, Izaskun Zeberio36, Inigo Olazabal Eizaguirre37, Norma Gutiérrez, MD, PhD38, Víctor Navarro Garces, MSc39, Alejandro Martín Gracía-Sancho, MD PhD40, Pau Abrisqueta, MD, PhD41, Gloria Iacoboni, MD42
1 Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Institute of Oncology, Barcelona, Spain
2 Hospital Universitario Gregorio Marañón, Madrid, Spain
3 Hospital Universitario 12 de Octubre, Madrid, Spain
4 Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain
5 Hospital Universitari Vall d'Hebron, Barcelona, Spain
6 Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
7 Hospital General Universitario de Alicante / Doctor Balmis, Alicante, Spain
8 Hospital Donostia, San Sebastian, Spain
9 University Hospital of Salamanca-IBSAL, Salamanca, Spain
10 Hospital Clinic de Barcelona, Barcelona, Spain
11 Hospital Universitario Juan Raóm Jiménez, Huelva, Spain
12 Institut Català d’Oncologia, Hospitalet del Llobregat, Hospitalet de Llobregat, Spain
13 Hospital Universitario de Cabueñes, Gijón, Spain
14 Hospital Dr Negrin, Las Palmas de Gran Canaria, Spain
15 Hospital Doctor Peset, Valencia, Spain
16 Calle Miguel Servet, Calatayud, Spain
17 Hospital General Universitario Morales Meseguer, Murcia, Spain
18 Hospital Universitario de Burgos, Burgos, Spain
19 Hospital La Paz, Madrid, Spain
20 Hospital Universitario De La Princesa, Madrid, Spain
21 Hospital Universitario Nuestra Señora De Candelaria, Santa Cruz de Tenerife, Spain
22 Hospital Universitario de Navarra, Pamplona, Spain
23 Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
24 Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
25 Urgencias Hospital de Basurto, Bilbao, Spain
26 Hospital de Segovia, Segovia, Spain
27 Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Institute of Oncology, Barcelona, Spain
28 Hospital de Donosti, San Sebastián, Spain
29 Hospital Del Mar, Barcelona, Spain
30 Hospital Royo Villanova, Zaragoza, Spain
31 Hospital Universitari Son Llàtzer, Palma, Spain, IdisBa, Palma, Spain
32 Hospital Universitario Marqués De Valdecilla, Santander, Spain
33 Hospital Universitari Son Espases, Palma, Spain, IdisBa, Palma, Spain
34 Hospital General La Mancha Centro, Alcázar de San Juan, Spain
35 Hospital Universitario Virgen Macarena, Sevilla, Spain
36 Hospital de Donosti, San Sebastián, Spain
37 Hospital de Donosti, San Sebastián, Spain
38 University Hospital of Salamanca-IBSAL, Salamanca, Spain
39 Vall d'Hebron Institute of Oncology, Barcelona, Spain
40 University Hospital of Salamanca-IBSAL, Salamanca, Spain
41 Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Institute of Oncology, Barcelona, Spain
42 Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Background: Extranodal disease (END) is an established adverse prognostic factor in B-cell lymphomas across multiple treatment strategies, but data focused on patients with follicular lymphoma (FL) treated with CD20/CD3-targeted bispecific antibodies (BsAbs) remain scarce. We evaluated the impact of END burden and anatomical distribution in patients with relapsed/refractory (R/R) FL receiving BsAb monotherapy.

Methods: We performed a retrospective multicenter study of patients with R/R FL treated with single-agent CD20/CD3 BsAbs within the Spanish GELTAMO registry. Responses were assessed according to Lugano criteria. The primary objective was to evaluate the impact of baseline END presence, number of extranodal sites, and site-specific involvement on response and survival. Complete response rate (CRR), duration of response (DoR), progression-free survival (PFS) and overall survival (OS) were analyzed using Cox and logistic regression models respectively. Restricted cubic splines explored the relationship between extranodal burden and survival outcomes.

Results: Of 86 R/R FL patients in the registry, 75 (87%) with available baseline extranodal data comprised the study population. Median age was 66 years, 40 (53%) were male, and 46 (61%) had END at BsAb initiation. Cubic spline analysis identified ≥2 extranodal sites as a statistically significant and clinically meaningful cut-off, distinguishing a high-risk subgroup of 20 (27%) patients vs 55 (73%) with involvement of 0-1 extranodal sites. Baseline characteristics were similar between both groups, except for more advanced stage disease and higher FLIPI scores in patients with ≥2 extranodal sites, consistent with the inherent collinearity among these variables, and a higher rate of anemia (58% vs 26%).

Regarding safety, cytokine release syndrome (CRS) occurred in 41 (55%) patients, categorized as grade 1, 2 and 3 in 55% , 42% and 3%, respectively. Immune effector cell-associated neurotoxicity syndrome was observed in 2 (3%) patients, and both events were grade 1. Patients with ≥2 extranodal sites had a significantly higher incidence of any-grade CRS, compared with 0-1 extranodal sites (82% vs 45%; p<0.01). However, the incidence of grade ≥2 CRS did not differ between groups (59% vs 38%; p=0.17).

In terms of efficacy, patients with ≥2 END sites had a significantly reduced CRR (26% vs 69%; p<0.01) and a shorter DoR (4 vs 33 months [HR 3.50; 95% CI 1.29–9.52; p=0.01]). In the multivariable analysis (MVA) including sex, age >60 years, elevated LDH, hemoglobin <12g/dL, POD24 status and bulky disease, ≥2 extranodal sites was the only independent predictor of lower CRR (OR 11.89;  p=0.03).

With a median follow-up of 11.3 months, the overall median PFS and OS were 17.0 months [95% CI 6–35.4] and not reached, respectively. A high extranodal burden was associated with inferior PFS (5.5 vs 24 months [HR 3.12; 95% CI 1.52–6.39; p<0.01]), maintained in the MVA (HR 6.33; 95% CI 1.26–30.10; p=0.03). No difference in OS was observed, with neither group reaching the median survival cut-off.

The most frequent anatomical patterns of extranodal involvement were bone/bone marrow (n=25; 33.3%), soft tissue (n=17; 23%), pleuropulmonary (n=8; 11%), gastrointestinal (n=7; 9%), hepatic (n=4; 5%), renal (n=2; 2.7%), breast (n=1; 1%), and other extranodal sites (n=4; 5.3%). Bone/bone marrow involvement was associated with inferior PFS in the univariable analysis but was not maintained in the MVA. No other individual extranodal site predicted outcomes after adjustment for clinically-relevant covariates.

Twenty-five patients (25/75, 33.3%) had documented disease progression after BsAbs and END assessment at that timepoint; neither the prevalence (61% vs 64%) nor the extent of END sites (median 1 vs 1) changed significantly following relapse after BsAb therapy.

Conclusions: Involvement of ≥2 extranodal sites was an independent predictor of worse treatment outcomes in R/R FL patients treated with CD20/CD3 BsAbs. Extranodal burden represents a simple and clinically applicable stratification marker that may identify patients requiring risk-adapted treatment strategies.

Marc Bosch Schips, MD: No relevant conflicts of interest to declare.